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Suinnr In a phase I trial the toxicity and immunomodulatonr effects of combined treatment with
intravenous (i.v.) bispecific monoclonal antibody BIS-I and subcutaneous (s.c.) interleukin 2 (IL-2) was
studied in renal cell cancer patients. BIS-1 combines a specificity against CD3 on T lymphocytes with a
specificity against a 40 kDa pancarcinoma-associated antigen. EGP-2. Patients received BIS-1 F(ab'):
fragments intravenously at doses of 1. 3 and 5 ;g kg-' body weight during a concomitantly given standard s.c.
IL-2 treatment. For each dose. four patients were treated with a 2 h BIS-1 infusion in the second and fourth
week of IL-2 therapy. Acute BIS-1 F(ab'):-related toxicity with symptoms of chills, peripheral vasoconstriction
and temporary dyspnoea was observed in 2 4 and 5 5 patients at the 3 and 5 jlg kg-' dose level respectively.
The maximum tolerated dose (MTD) of BIS-1 F(ab'), was 5;jg kg-'. Elevated plasma levels of tumour
necrosis factor m (TNF-x) and interferon gamma (IFN-y) were detected at the MTD. Flow cytometric analysis
showed a dose-dependent binding of BIS-1 F(ab')2 to circulating T lymphocytes. Peripheral blood
mononuclear cells (PBMCs). isolated after treatment with 3 and 5 jg kg-' BIS-1. showed increased specific
cytolytic capacity against EGP-2+ tumour cells as tested in an ex ivo performed assay. Maximal killing
capacity of the PBMCs. as assessed by adding excess BIS-1 to the assay. was shown to be decreased after
BIS-1 infusion at 5 jig kg-' BIS-I F(ab'),. A BIS-1 F(ab'), dose-dependent disappearance of circulating
mononuclear cells from the peripheral blood was observed. Within the circulating CD3+CD8 lymphocyte
population. LFA-Im-bright and HLA-DR+ T-cell numbers decreased preferentially. It is concluded that i.V.
BIS-I F(ab'). when combined with s.c. IL-2. has a MTD of 5 jLg kg-'. The treatment endows the T
lymphocytes with a specific anti-EGP-2-directed cytotoxic potential.
Interleukin 2 (IL-2)-based immunotherapy has reproducible
activity in selected tumours. Renal cell carcinoma (RCC) and
melanoma are the malignancies most sensitive to this form of
treatment. Objective responses are observed in approximately
20% of patients with RCC. with durable complete remissions
occurring in 5% (Rosenberg et al.. 1989). Subcutaneous (s.c.)
administration of IL-2 has been found to prevent an impor-
tant part of the toxicity associated with the use of intra-
venous (i.v.) IL-2 and has been shown to give rise to
immunological and anti-tumour effects similar to the i.v.
treatment (Sleijfer et al., 1992: Janssen et al., 1993). Still.
most RCC and melanoma patients and almost all patients
with other tumour types do not respond to IL-2 treatment.
A new form of immunotherapy in which the specific bind-
ing properties of monoclonal antibodies (MAbs) and the
killing capacities of cytotoxic effector cells are combined,
using bispecific monoclonal antibodies (BsMAbs), has been
the subject of several recent studies. BsMAbs used in this
treatment concept are composed of the antigen-binding
subunits of two different MAbs, giving rise to one antibody
with two specificities. BsMAbs which combine specificities
against tnggering molecules on cytotoxic effector cells on the
one hand and tumour-associated antigens (TAAs) present on
target cells on the other are able to redirect the lytic capcity
of the effector cell towards a chosen tumour target cell
(Bolhuis et al.. 1991). This concept has been studied in vitro
and in vivo for a number of different effector and target cell
populations (Kerr et al.. 1990: Fermni et al.. 1991: Mezzan-
zanica et al.. 1991; Segal et al.. 1991; Weiner & Hillstrom,
1991. Weiner et al.. 1993). Results indicate that BsMAb-
redirected effector cells can specifically kill tumour cell lines
in vitro and established tumours in vivo in animal models. A
start has been made to exploit this treatment modality for the
treatment of cancer patients. In glioma and carcinoma
patients. BsMAbs were shown to induce anti-tumour activity
as well as inflammatory reactions upon local transfer of ex
vivo-activated autologous peripheral blood mononuclear cells
(PBMCs) preincubated with a BsMAb reactive with the CD3
complex on T lymphocytes and a TAA present on the tumour
cells (Nitta et al.. 1990: Bolhuis et al.. 1992: Kroesen et al..
1993). To investigate the therapeutic possibilities of BsMAbs
further. i.e. for systemic anti-tumour treatment. we have
started a phase I study of i.v. administration of BsMAb. The
BsMAb used, BIS-1. is reactive with both the CD3 complex
on all T lymphocytes and a pancarcinoma-associated antigen
called epithelial glycoprotein (EGP-2) (De Leij et al.. 1993).
Antibodies recognising this carcinoma-associated protein have
been clustered as SCLC cluster 2 and include CO17-lA and
AUA-1 (Herlyn et al.. 1979; Beverly et al., 1988: De Leij et
al.. 1993). EGP-2 is a membrane-bound 40 kDa glycoprotein
which is highly expressed by most carcinomas and is not shed
from the cell membrane (Steplewski et al.. 1981). EGP-2 was
also found to be present on all renal cell carcinomas tested
by us. although often to a low extent (our own observation).
Its expression on normal tissue is restricted to simple epi-
thelia (Varki et al., 1984). and the antigen is described in a
number of clinical studies as a target antigen for MAb-based
immunotherapies (Sindelar et al.. 1986; Samonigg et al..
1992; Kroesen et al.. 1993). In the present study BIS-1 was
combined with s.c. IL-2 treatment. This combination was
chosen because target cell lysis by BsMAb-redirected
cytotoxic T lymphocytes (CTLs) has been shown to be de-
pendent on preactivation of lymphocytes (Bach et al.. 1989;
De Jong et al.. 1990: Kerr et al.. 1990). This implies that
effective in vivo targeting of T lymphocytes towards tumour
cells by BsMAb should meet the condition of prior immune
activation which, in the case of local treatment settings. can
be done by ex vivo activation of autologous immune cells
(Nitta et al.. 1990: Weiner & Hillstrom. 1991). Immune
activation in vivo, including T-cell activation. can be attained
by s.c. IL-2 therapy (Janssen et al.. 1993). Furthermore.
homing of lymphocytes into tumour tissue, which appears to
be a prerequisite for effective cellular immunotherapy. might
be enhanced by IL-2 (Fisher et al.. 1989: Pankonin et al..
1990).
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The present phase I trial studies the feasibility, toxicity and
immunomodulatory effects ofi.v.-adi i BIS-1 in com-
bination with s.c.-given IL-2 in patients with disseminated
RCC who were unresponsive to previous single-agent s.c.
IL-2 treatment. F(ab% fragments of BIS-1 were made and
used in the present study to prevent possible aspecific toxicity
resulting from the interaction of the Fc part of the BsMAb
with FcR+ cells such as monocytes and the CD3-recogn iing
part of the antibody with T cells, resulting in a cross-linking
of the two cell types.
Materials and methods
Patients
All patients had a histologically confirmed diagnosis of
disseminated RCC not responding to single-agent s.c. IL-2.
The patients had bidimensionally measurable tumour lesions,
a performance status of <2 (World Health Organization,
WHO scale), an age of >18 years, an estimated life expec-
tancy of more than 3 months, a rest period of at least 2
weeks after previous immunotherapy and an adequate hae-
matological function (white blood count >4,000mm-3,
platelet count > 120,000 mm-3, haematocrit >30%).
Patients with uncontrollable disease apart from the tumour,
with renal dysfunction as indicated by serum creatinine level
> 120ytmol 1I or with hepatic dysfunction as indicated by
serum bilirubin levels >30 mmol I' were excluded. Addi-
tional exclusion criteria were concurrent treatment with cor-
ticosteroids or prior treatment with mouse antibodies. The
study was approved by the University Hospital Groningen
Medical Ethical Committee. Written informed consent was
obtained from all patients before the start of treatment.
Preparation andpurification ofBIS-1
The BIS-l-producing quadroma was made in our department
by fusion of the hybridomas RIV-9 and MOC-31, producing
anti-CD3 (IgG3) and anti-EGP-2 (IgGl) antibodies respec-
tively, according to a procedure described by De Lau et al.
(1989). Large-scale production ofBIS-1 was done in a hollow
fibre culture system (Endotronics, Minniapolis, MN, USA)
under good manufacturing practice (GMP) guidelines.
Purification of the hybrid antibodies (IgG3/IgGl) from
parental-type antibodies (IgG3 and IgGl), also produced by
the quadroma, was done by protein A column chromato-
graphy. Hollow fibre culture supernatant was loaded onto
the column at pH 7.3 and the different IgG fractions were
eluted successively by lowering the pH stepwise. The BIS-1-
containing fraction, eluted with 0.1 M sodium acetate, pH 4.0,
was then digested by pepsin (Worthington, Freehold, NJ,
USA) using a final BIS-l-pepsin ratio of 100:1 (w/w). Diges-
tion was performed at 37C for 4 h, immediately followed by
G150 Sephadex gel filtration to separate BIS-1 (F(ab% from
undigested IgG, fragmented Fc portions and pepsin. The
purified BIS-1 F(ab') solution was adjusted to a concentra-
tion of 0.2 mgml-' with 0.9% sodium chloride. HSA (Insti-
tute Merieux, Lyon, France) was added to a concentration of
0.5% and the preparation was then passed through a 0.22ptm
filter and stored sterile at 4-C. Sterility of the BIS-1 F(ab')2
preparation was confirmed by culturing in Clausur medium.
The BIS-1 F(ab'% preparation was pyrogen free as tested in
Linus amoebocyte lysate assay and by intravenous admini-
stration of the preparation to rabbits. Abnormal toxicity was
tested for by administration of the BIS-1 F(ab') preparation
to mice and guinea pigs both intravenously and intraperi-
toneally according to the protocol ofthe Dutch Pharmacopee
IX (1980) and was found to be absent. The ability of the
BIS-I F(ab% preparation to redirect the lytic activity of T
lymphocytes towards EGP-2-positive tumour cells was as-
sessed in a standard 5'Cr-release assay in which in vitro-
activated T lymphocytes (effector lymphocytes, see below)
were used as effector cells and GLC-IM13 (EGP-2-positive),
GLC-1 (EGP-2-negative) and P815 (FcR-positive) were used
as target cells. The target cell line P815 was used to check
whether or not the BIS-i F(ab% preparation was devoid of
undigested Fc containing BIS-1 IgG.
Treatment
Patients received daily subcutaneous injections of 18 x 106 IU
of IL-2 (Proleukin, EuroCetus Amsterdam, The-Netherlands)
in a 5 day weekly cycle for four consecutive weeks as
previously described (Sleijfer et al., 1992). The dose in the
first 2 days of the second, third and fourth weeks was
reduced to 9 x I06IUday'- followed by 3 days of
18 x 106 IU day-'. Acetaminophen 250-500 mg orally every
4-6 h was given to suppress pyretic reactions. The BIS-1
F(ab'), BsMAb was administered in 100 ml of 0.9% sodium
chloride as a 2 h i.v. infusion.
Study protocol
Consecutive cohorts of at least four patients were treated at
each dose level in a dose-escalating phase I trial design. Dose
levels of 1, 3 and 6uLg kg-' body weight were planned to be
studied. The antibody was administered in the rebound phase
of a preceding 5 day s.c. IL-2 cycle when the number of
peripheral blood T lymphocytes was high (Janssen et al.,
1993). The first two patients from a particular dose level
received the antibody on days 8 and 22 and the following
two patients received the antibody on days 8 and 23, in order
to study the effects of the antibody both before (day 8 and
22) and during (day 23) a cycle of IL-2 administration. On
the day of the antibody infusion, IL-2 was administered 4 h
after the end of infusion. The end point of the study was
dose-limiting toxicity, defined as toxicity exceeding WHO
grade II. The maximum tolerated dose (MTD) was defined as
the dose level below that producing dose-limiting toxicity.
Immunological parameters, including cytological and func-
tional binding of BIS-l F(ab'),, were monitored before and at
the end of the antibody infusion. Quantification of BIS-1
F(ab'), binding to T lymphocytes was done by a flow
cytometry-based procedure. Functional binding of BIS-1
F(ab')2 to T lymphocytes was assessed in a standard 5"Cr-
release cytotoxicity assay against the target cell lines GLC-
IM13 (EGP-2-positive) and GLC-1 (EGP-2-negative).
Toxicity- and response monitormg
Before treatment, patients were staged with a full physical
examination, determination of WHO performance status,
renal, liver, thyroid and haematological function, an ECG
and radiological recording of disease extension. During treat-
ment weight and temperature were recorded daily and renal,
liver and haematological functions were determined weekly.
Thyroid function was determined before and after the whole
treatment. Blood samples were taken before the start and at
the end of infusion of BIS-1 F(ab'), for analysing BIS-1
F(ab'% binding to T lymphocytes and the cytotoxic capacity
of isolated PBMCs in vitro. Vital functions were measured
every 30 min during the infusion, every 2h thereafter and
three times daily in the 5 days during which the patients were
hospitalised. Toxicity was scored according to standard
WHO criteria (Anonymous, 1979). Dose modifications were
planned as follows. In case of toxicity during the BIS-l
F(ab')2 infusion exceeding WHO grade II the infusion was
abrogated. In the case of weight gain > 5% or an increase in
serum creatinine level of more than 100% or a decrease in
systolic tension of 25% during the rest of treatment, the IL-2
was discontinued. Treatment could be reinstituted when toxi-
city had returned to below a grade I level. If IL-2 had to be
withheld for more than 5 days the patient went off study.
Response was monitored by radiographic techniques as ap-
propriate. Tumour elevations were repeated after 4 weeks of
treatment and every 3 months thereafter. A complete re-
sponse was defined as the disappearance of all evidence of
tumour for a minimum of 4 weeks; a partial response was
recorded when a 50% or greater decrease in the sum of the654 B.J. KROESEN et al.
products of all diameters of evaluable lesions was reached.
Patients with a response less than paritial or an increase of
less than 25% for at least 3 months were classified as having
stable disease. Progression was defined as an increase of more
than 25% or the development of new lesions.
PBMC isolation
PBMCs were obtained from heparinised peripheral blood.
Isolation was done by density centrifugation of diluted (1:1
in phosphate-buffered saline PBS) blood on Lymphoprep
(Nycomed, Oslo, Norway) at 2,400 r.p.m. for 20 min. The
PBMC fraction was washed twice by resuspension in RPMI-
1640 (Gibco Europe, Breda, The Netherlands) and centri-
fugation at 1,800 (first time) and 1,200 (second time) r.p.m.
for 10 min. After isolation, PBMCs were collected in com-
plete medium consisting of RPMI-1640 supplemented with
2% heat-inactivated human pooled serum, 2 mM glutamine
and 60iLg ml-' gentamicin.
Antibodies usedforflow c}tometry
For phenotyping of T lymphocytes and assessment of BIS-1
F(ab'} binding to T lymphocytes, the following MAbs were
used: fluorescein isothiocyanate (FITC)- or phycoerythrin
(PE)-labelled anti-Leu-4 (CD3), biotinylated anti-Leu-2a
(CD8), FITC-labelled anti-LFA-Ia (CD1 la), PE-labelled
HLA-DR (Becton Dickinson, Mountain View, CA, USA),
bitonylated goat anti-mouse Ig (GaM-biotin) and
biotinylated goat anti-mouse Ig (GaM-biotin) (Southern
Biotechnologies, Cambridge, MA, USA).
Flow cYtometric analysis
CD3 occupancy by BIS-I F(ab'% was assessed using an
indirect immunofluorescence staining procedure in which
streptavidin-PE (SAPE) (Becton Dickinson) was used to
amplify the BIS-l F(ab')2 detection with biotinylated goat
anti-mouse antibodies (Zola et al., 1990). A 100jtl aliquot of
peripheral EDTA blood or isolated PBMC samples were
incubated with phosphate-buffered saline (PBS) or a saturat-
ing amount of BIS-1 F(ab%) (21Lgml-') at 4°C for 30 min.
After one wash with 2 ml of PBS and 50 l GaM-biotin or,
as a control for aspecific binding of the conjugate, GaR-
biotin (each 40 x diluted in PBS containing 1% pooled
human serum) was added to the cell pellet and incubated at
4'C for 30min. After one wash with 2ml of PBS, 10ILI
streptavidin-PE was added to the cell pellet and the samples
were incubated at 4°C for 30 min. Cells were resuspended in
2 ml of FACS lysing solution (Becton Dickinson), incubated
for 10 min at room temperature, washed once with PBS and
resuspended in a final volume of 150iLl PBS for flow
cytometnc analysis. The CD3 occupancy was calculated ac-
cording to the following formula:
MFIt = x (PBS G3EM-bio SAPE) - MIt = (PBS GmR-bio SAPE)
MFIt =(BxSMI GEM-bioSAPE) -MFIt= (BIS-I GaR-bo SAPE)
in which the sequential incubation steps are given between
brackets, MFI is the mean fluorescence intensity, SAPE is
streptavidin-PE and t=x represents either t=Oh (before
the infusion) or t =2 h (after the infusion).
Changes in leucocyte numbers as induced by the treatment
were analysed by a Coulter Leucocounter (Coulter Elec-
tronics, Hilaleah, FL, USA). Changes occurring within the
CD3/CD8 double-positive cell population as induced by the
treatment were analysed by three-colour flow cytometry.
CD8-biotin/streptavidin-allophycocyanin (APC) and CD3-
PE or CD3-FITC was used to select for CD3/CD8 double-
positive T lymphocytes, and CDIla-FITC and HLA-DR-PE
conjugates were used to analyse the presence of LFA-la- and
HLA-DR-positive ceUs within the CD3/CD8 cell population.
Staining was performed on 100 ll of peripheral EDTA blood
obtained from the patient just prior to (t =0 h) and directly
after (t = 2 h) BIS-1 infusion. In the first step, CD8-biotin
was allowed to bind at 4°C for 30 min followed by one wash
with 2 ml of PBS. The second step included the addition of
either streptavidin-APC, CD3-FITC, HLA-DR-PE or
streptavidin-APC, CD3-PE, CD1 la-FITC to the re-
suspended cell pellet and incubation for another 30 min at
4°C. The cell suspension was resuspended in 2 ml of FACS
lysing solution, incubated for 10 min at room temperature,
washed once with 2 ml of PBS and resuspended in a final
volume of 150pl of PBS for analysis. The samples were
analysed on a Coulter Elite Cytometer (Coulter Electronics)
using an argon laser (488 nm) for FITC and PE excitation
and a He/Ne (623 nm) laser for excitation of APC.
Immunofluorescence emission was measured using a 525 nm
bandpass filter for FITC, a 575 nm bandpass filter for PE
and a 675 nm bandpass filter for APC.
Effector lymphocytes
In order to test the activity of the BIS-1 F(ab')2 preparation,
PBMCs isolated from healthy volunteers were activated by
incubating the cells for 3 days in complete medium supple-
mented with 5% (giving about 0.5 gigml-' IgG end concen-
tration) culture supernatant of the mitogenic anti-CD3 MAb
WT-32 (Tax et al., 1983), followed by washing and incuba-
tion for two additional days in complete medium supple-
mented with 60 IUml-I IL-2 (EuroCetus, Amsterdam, The
Netherlands). To assess functional binding of BIS-1 F(ab'),
to T lymphocytes in the clinical study, freshly isolated
PBMCs drawn from the patients just before and after the 2 h
antibody infusion were used directly in the 5"Cr-release
cytotoxicity assay.
Target cell lines
GLC-IM13 (EGP-2-positive) and GLC-1 (EGP-2-negative)
are small-cell lung cancer (SCLC)-derived cell lines (De Leij
et al., 1985). P815 is a FcR-positive mouse mastocytoma cell
line. These cell lines were cultured according to routine pro-
cedures in RPMI-1640-based medium supplemented with
14% heat-inactivated fetal calf serum, 2 mM glutamine
60 LgmlI-' gentamicin (Schering, Kenilworth, USA),
0.05 mM P-mercaptoethanol and 1 mM sodium pyruvate at
37TC in a humidified atmosphere containing 5% carbon diox-
ide.
SICr-releaseassay
5'Cr-release assays were performed according to standard
procedures to assess BIS-1-redirected T-cell cytotoxicity. All
determinations were done in triplicate in the presence of
60 IU ml-' IL-2. Before the assay, 5 x 106 target cells (GLC-
lM13, GLC-1 or P815) were suspended in 100gp1 of culture
medium containing 3.7 MBq of ['CrJsodium chromate
(Amersham, UK) and incubated for 1 h at 37C in a
humidified, 5% carbon dioxide-containing atmosphere. Un-
bound V'Crjsodium chromate was removed by washing the
cells three times with medium. A 501gI aliquot of medium
containing 0.4 gml-' BIS-1 F(ab') (giving a final concen-
tration of 0.1 gigml-' during the assay) or not was pipetted
into a 96-well round-bottom microtitre plate (Greiner no.
650180) and incubated with 50gi1 of 2.5 x I04 or 2.5 x 1O0
effector lymphocytes for 15 min at room temperature. Subse-
quently, 100 gl of medium containing 2.5 x 103 5'Cr-labelled
target cells was added to each well to give effector to target
(E/T) ratios of 1, 10 and 100 in a final volume of 200gil. The
microtitre plates were centrifuged at 500 r.p.m. for 2 min and
incubated at 37C in 5% carbon dioxide for 4 h. After the
incubation, the plates were centrifuged at 1,000 r.p.m. for
5 min and 100gil samples taken from the supernatant were
counted in a gamma counter for 5 min. Cell lysis was cal-
culated from the percentage 5'Cr released, according to the
formula:
Experimental release -spontaneous release x 100%
Maximal release - spontaneous release
Maximal release was determined from a sample to which
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effector cells. Spontaneous release was determined from a
sample to which 501tl of medium was added instead of
effector cells.
1or
Cvtokine release
Antibody-based capture ELISAs were used to assess TNF-x
(British Bio-technology, Oxford, UK) and IFN-y
(Eurogenetics. Leuven, Belgium) according to the manufac-
turer's instructions. Blood plasma was isolated by centrifuga-
tion of EDTA-containing peripheral blood samples at
2,500 r.p.m. at 4°C for 5 min immediately after collection.
The cell fraction was discarded and the plasma samples
stored at -20'C until use.
Statistics
Changes in leucocyte count, phenotype and function were
statistically analysed using the Wilcoxon test for paired
observations. A two-sided x-level of 0.05 was considered
significant.
Results
In vitro effectiveness and characteristics ofBIS-J F(ab')2
The purified BIS-1 F(ab')2 fragment preparation used in this
study was analysed by SDS-PAGE. No undigested IgG
could be detected (data not shown). In agreement with this,
the preparation induced no Fc-mediated cytotoxicity of
activated cytotoxic T lymphocytes towards the FcR-positive
target cell line P815. whereas undigested BIS-I IgG did
(Figure 1). BIS-1 F(ab')2 proved to be equally as able as
undigested BIS-1 IgG of redirecting cytotoxic T lymphocytes
towards EGP-2-positive. but not EGP-2-negative, tumour
cells. Optimal target cell lysis is induced in both cases at a
concentration of 0.1 g ml1' BIS- in which the actual BIS-I
F(ab'). concentration was corrected for its lower molecular
weight. The degree to which CD3 molecules on T lym-
phocytes are occupied with BIS-1 at this concentration is
27%. but even at a CD3 occupancy as low as 2% (1 ng ml-')
considerable target cell-directed cytotoxicity is induced
(Figure 1).
Phase I stud!
From October 1992 until June 1993. 14 patients with
advanced RCC who showed no response after 4 weeks of s.c.
IL-2 treatment were entered. The characteristics of the
patients are listed in Table I. All patients were eligible for
evaluation of toxicity. Side-effects arising from the BIS-1
F(ab'). administration are listed in Table II. This dose-
dependent toxicity could be discriminated from the toxicity
associated with IL-2 by its acute and rapidly transient char-
acteristics. At the 1 gg kg-' dose level no toxicity was
observed. Toxicity occurred in two out of four patients at the
3 yg kg-' dose level and consisted of chills, peripheral
vasoconstriction with rise in diastolic tension, temporary
dyspnoea and fever. Symptoms started suddenly in all
patients. approximately 100min after the start of infusion,
and lasted 15-30min. except for the fever, which started
approximately 30 min after the end of the infusion and lasted
for 1-2 h. No neurotoxicity was observed after administra-
tion of the BIS-I F(ab').. In the first patient at the 6pg kg-'
dose level, severe rigors started 1 h after the start of infusion,
and became accompanied by increasing dyspnoea with signs
of cyanosis, whereupon the infusion had to be abrogated.
Symptoms resolved gradually over the next 4-6 h except for
fever. The patient had received a total dose just over
5Jg kg'. On day 22. a dose of 5;g kg-' could be admini-
stered to the same patient as a 2 h infusion, producing tox-
icity with chills to a grade I toxicity. No further dose escala-
tion was attempted. A total of five other patients were
treated at a 5ytg kg-' dose level, producing grade I-II tox-
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Figure 1 Cytolytic activity of in vitro-activated T lymphocytes of
healthy volunteers against the EGP-2-positive target cell line
GLC-lM13 (@, +) and the FcR-positive target cell line P815
(V, A) induced by various concentrations of BIS-1 IgG (@. V)
and BIS-1 F(ab')2 (+, A). Cell lysis was assessed in a 4h
5"Cr-release assay at an E T ratio of 100:1. CD3 occupancy ( x )
of T lymphocytes by the indicated concentrations of BIS-I
F(ab'), was measured as described in the Materials and methods
section.
Tabl I Patients characteristics
n %
Patients 14
Female/male 6 8
Age (years)
Median 58
Range 48-70
WHO performance
0 3 21
1 7 50
2 4 29
Prior therapy
Nephrectomy 6 43
Chemotherapy 0 0
Immunotherapy 14 100
Tumour localisations
Primary 8 57
Lung 9 64
Bone 5 36
Other 4 29
Number of metastatic sites
1 2 14
2 8 57
3or more 4 11
icity in all patients. This dose was considered the MTD. No
difference in toxicity was observed between the administra-
tion of the antibody on days 8 and 22, before the start of a
new IL-2 cycle, or on day 23, during an IL-2 cycle. There
was no correlation between sex, age, performance status,
prior nephrectomy or the presence of lung metastases and
toxicity.
Toxicity during subcutaneous IL-2 treatment was similar
to previous findings with s.c. IL-2 monotherapy (Sleijfer et
al., 1992) and consisted of transient inflammation and local
induration at the injection sites in all patients. The residual
nodular lesions resembling subcutaneous lipomas disappeared
slowly during a 2-4 month period. Flu-like symptoms with
fever and chills occurred in all patients, leading to a grade
I-II toxicity in 21/56 and 29,'56 treatment weeks respectively.
Nausea/vomiting grade I, II and III occurred during 25/56,
20/56 and 1/56 weeks respectively, while diarrhoea was
observed during 5/56 weeks reaching grade I only. Hypoten-
sion was not observed. Transient elevations of y-glutamyl-
transpeptidase and alkaline phosphatase were observed in
34% and 21% of patients respectively. One patient receiving656 B.J. KROESEN et al.
Table II Toxicity and response of treatment
Dose Toxicity 1 Toxicitv 2
No. Sex (fgkg-' da! 8 da! 22 or 23 Response
I IM - - SD
2 M I - - PD
3 F I - - SD
4 F I - - PD
5 F 3 - - PD
6 M 3 Chills. fever Chills PD
7 F 3 SD
8 M 3 Chills PR. 6 months
9 M 6-*5' Chills. dyspnoea. Chills PD
fever
10 F 5 Chills. temporarv. Chills SD
dyspnoea. fever
11 M 5 Chills PD
12 F 5 Chills Chills PD
13 M 5 Chills, temporary Chills. temporary PD
dyspnoea. fever dyspnoea, fever
14 M 5 Chills, temporary SD
dyspnoea. fever
-At day 8 infusion was abrogated at t= 1.5 h. giving an effective dose of approximately
5 jig kg-'. At day 22 5 jig kg-' was given in a 2 h infusion. F. female: M. male: PR. partial
remission: SD. stable disease: PD. progressive disease.
BIS-1 (at the 5 gg kg-' dose level) had gradual progression
of pre-existent renal dysfunction at the end of IL-2 therapy.
resulting in a creatinine elevation to grade III toxicity.
Thyroid dysfunction was observed in one patient. Peripheral
blood lymphocyte counts dropped temporarily upon admini-
stration of the BIS-1 F(ab')2. as will be discussed below, but
these numbers returned to normal values 24 h after the
infusion. During subsequent IL-2 treatment mean peripheral
blood lymphocyte count rose from 1.8 (s.d. 1.0) to a maxi-
mum of 4.8 (s.d. 2.6) x I09'1'. while eosinophil counts rose
from 0.3 (s.d. 0.3) to 4.9 (s.d. 3.9) x 109l-'. No additional
toxicity. especially no enhanced mucositis. diarrhoea or skin
toxicity. from the BIS-1 F(ab')2 antibody on top of the
IL-2-related toxicity was observed during the rest of the IL-2
treatment course when compared with previous s.c. IL-2
monotherapy (Sleijfer et al.. 1992).
Response to treatment
All 14 patients were assessable for response after 4 weeks of
treatment. One partial response in a patient with lung meta-
stasis who received 3 gLg kg-' was observed and lasted 6
months. Five patients showed stable disease for at least 3
months and eight patients exhibited progressive disease.
In vivo occupancy ofCD3 by BIS-I
Immediately after ending the i.v. BIS-1 infusion, the degree
to which available CD3 molecules on T lymphocytes were
occupied with BIS-1 was assessed by flow cytometry. Figure
2 summarises the results obtained from patients treated with
different doses of BIS-1 F(ab')2. At 1 iLg kg-' BIS-I F(ab')2,
the presence of mouse antibodies bound to T lymphocytes
was just detectable and the degree to which CD3 molecules
were occupied was determined to be 1.5% (s.d. 0.4). At
3 gig kg-' BIS-1 F(ab')2, binding of the BsMAb to T lympho-
cytes was clearly detectable and CD3 occupancy was 4%
(s.d. 0.9), whereas at 5 gLg kg-' BIS-1 F(ab')2 CD3 occupancy
was 6% (s.d. 3). Within the dose levels described no
differences in CD3 occupancy were observed between the first
(day 8) and the second (day 22 or 23) infusion of BIS-I
F(ab')2. After PBMC isolation, in order to perform 5'Cr-
release assays, the CD3 occupancy by BIS-I F(ab'), was
measured again and proved to be reduced from 4% to 2.5%
(s.d. 0.6) and from 6% to 3% (s.d. 0.5) for doses of 3 and
5;gg kg-' BIS-I respectively. The CD3 occupancy by BIS-l
F(ab')2 was found to decrease in the next hours (not
shown).
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Fugwe 2 Mean CD3 occupancy of T lymphocytes in vivo,
measured directly after infusion with 1 (four patients, n = 8), 3
(four patients, n=8) and 5 (six patients, n= 12) jigkg' BIS-1
F(ab) (solid bars). After PBMC isolation, done to perform
cytotoxicity assays, the CD3 occupancy of T lymphocytes by
BIS-1 F(ab'), was measured again (0). ND, not done.
Functional analysis ofBIS-I binding
The ability of in vivo BIS-1 F(ab'}-loaded T lymphocytes to
exert specific anti-tumour activity was assessed in an in vitro
5'Cr-release assay. PBMCs isolated from peripheral blood
obtained just before (t =0 h) and directly after (t = 2 h)
infusion with BIS-1 F(ab')2 were incubated with 5'Cr-labelled
EGP-2-positive and -negative target cells at E/T ratios of 1,
10 and 100. Both at t = 0 h and at t = 2 h, the assay was also
performed in the presence of additional BIS-1 F(ab}
(0.1 igml-') added to the assay to assess the maximal
redirected cytotoxic capacity of the PBMC. Figure 3 shows
the results of the EGP-2-redirected cytolytic capacity of these
freshly isolated PBMCs at an E/T ratio of 100. PBMCs
isolated after infusion of 3gg kg-' BIS-1 F(ab'} showed
significantly higher specific anti-tumour activity than PBMCs
isolated before the infusion (P<0.04), indicating that the in
vivo bound BIS-1 endowed the T lymphocytes with a func-
tional anti-EGP-2 redirected cytotoxic capacity (see Figure
3a. t =0- and t = 2-). At this dose, maximal redirectedBIS-l AND IL-2 IN RENAL CANCER PATIENTS 657
cytotoxic capacity, before and after the infusion, as assessed
by adding 0.1 gml-' BIS-I F(ab')2 in vitro to the assay, was
approximately the same in all patients tested (see Figure 3a,
t =0+ and t = 2+). At 5 g kg-l, however, the maximal
redirected cytotoxic capacity after the 2 h infusion was found
to be significantly lower (P<0.005) than the maximal
redirected cytotoxic capacity before infusion using the same
E/T ratio (see Figure 3b, t=0+ and t=2+). Using the
EGP-2-negative target cell line GLC-1, no cytotoxicity could
be measured at any of the assessed doses or time points,
indicating that possible LAK activity did not interfere with
this assay (data not shown).
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Treatment-related cvtokine release
Since the observed toxicity in the patients treated at the
5yig kg-' BIS-l F(ab')2 dose level (Table II) might be ex-
plained by the release of secondary cytokines. serum levels of
TNF-a were assessed in patients treated at 3 and 5jug kg-'
before and at different time points after the infusion (Figure
4). Also IFN-y, a cytokine thought to be produced more
selectively by activated T cells, was measured in these
patients. At 3;tg kg-' no elevation of serum TNF-a or IFN-y
was found in two patients (nos. 7 and 8) tested. Administra-
tion of 5 Lg kg-' body weight BIS-l F(ab')2. however, evoked
TNF-a production up to 180 pgml1', and IFN-y production
up to 12 U ml' (patients 9 and 10 tested). Peak levels of
TNF-a were found 2 h after the start of the infusion. Peak
levels of IFN-y were detected 3 h after the start of the
infusion. Both TNF-a and IFN-'y had returned to almost
base levels 24 h after the infusion.
Leucocyte numbers and immunophenotyping
Infusion of BIS-1 proved to have profound effects on the
number of leucocytes present in the blood. Figures 5 and 6
show absolute numbers ofperipheral monocytes and lympho-
cytes before and after the 2 h infusion with BIS-1 F(ab'),. No
consistent changes in the numbers of granulocytes were
found to occur. At 1 figkg-' BIS-l F(ab'h no decrease in
peripheral monocyte and lymphocyte numbers was observed.
At 3 and 5f.g kg-' BIS-1 F(ab')2, however, especially
monocyte but also lymphocyte numbers were significantly
reduced in the blood (P<0.01 at 3jigkg-' and P<0.005 at
5 Lg kg-'). To analyse this phenomenon more specifically,
blood samples obtained from patients 11-14 were stained
with CD3, CD8, CDlla (LFA-lac) and anti-HLA-DR before
and after infusion with 5 Ag kg-' body weight BIS-I F(ab'),.
Changes occurring within the CD3/CD8 double-positive T-
lymphocyte population between the blood samples taken
before and after the infusion were analysed. Within the CD3/
CD8 double-positive T-cell population, LFA-lx-bright and
HLA-DR-positive cells disappeared from the blood to a
greater extent (P<0.02 and P<0.01 respectively) as a result
of BIS-1 F(ab'% infusion than the LFA-Ict-dim or HLA-DR-
negative cells (Table III).
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Fgure 3 Percentage target cell lysis (GLC-MI13) induced by
PBMCs isolated just before (t = 0 h) and directly after (t = 2 h)
infusion with 3 (four patients, n = 8) (a) and 5 (six patients,
n = 12) (b) tLg kg-' BIS-I F(ab')2. Cytolytic activity was assessed
in the absence (t=0-) and t=2-) and presence (t=0+ and
t=2+) of in vitro-added 0.1 gml' BIS-1 F(ab'). The data
shown are obtained at an ET ratio of 100:1. Median as well as
25 and 75 percentiles are shown as a box plot, whereas whiskers
range down to 5 and up to 95 percentile values. Asterisk in a
indicates a significant increase compared with the values at
t = 0-, (P<0.04, Wilcoxon test). Asterisk in b indicates a
significant decrease compared with the values at t =0+
(P<0.005 Wilcoxon test).
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Fige 5 Absolute numbers of monocytes (x 106ml-') just
before (t = 0 h) and directly after (t = 2 h) infusion with I (four
patients. n = 8) (a), 3 (four patients, n = 8) (b) and 5 (six patients,
n= 12) (c) iLg kg-' BIS-1 F(ab%. Median as well as 25 and 75
percentiles are shown as a box plot whereas whiskers range down
to 5 and up to 95 percentile values. Asterisk indicates a signifi-
cant reduction (P<0.005, Wilcoxon test) compared with the
values at t =O h).
Fugwe 6 Absolute numbers of lymphocytes (x 106ml-') just
before (t = 0 h) and directly after (t = 2 h) infusion with 1 (four
patients, n = 8) (a), 3 (four patients, n = 8) (b) and 5 (six patients,
n = 12) (c) iLg kg-' BIS-1 F(ab')2. Median as well as 25 and 75
percentiles are shown as a box plot whereas whiskers range down
to 5 and up to 95 percentile values. Asterisk indicates a
significant reduction (P<0.005, Wilcoxon test) compared with
the values at t = 0 h).
Table III Immunophenotyping of peripheral blood lymphocytes before and after BIS-1 F(ab')2
infusion at 5Lgkg-' body weight
Patient Day of CDllaC
no. treatment CD3a CD86 Bright Dim Ratio HLA-Dk
11 Day 8 t=Oh 66 21 63 35 1.8 49
t = 2 h 62 18 50 49 1.0 39
Day 23 t=0h 56 19 72 28 2.6 67
t = 2 h 58 17 44 36 1.2 52
12 Day 8 t=Oh 52 15 58 42 1.4 28
t=2h 53 13 43 56 0.8 12
Day23 t=Oh 33 19 56 44 1.3 12
t=2h 31 15 37 63 0.6 8
13 Day 8 t=0h 58 26 68 32 2.1 16
t=2h 54 28 68 32 2.1 10
Day 23 t=Oh 62 16 64 36 1.8 10
t=2h 73 16 45 54 0.8 4
14 Day 8 t=Oh 76 15 85 14 6.1 39
t = 2 h 83 14 67 32 2.1 26
Day 23 t=Oh 64 21 76 24 3.6 31
t = 2 h 59 22 56 43 1.6 19
aPercent positive cells of total lymphocytes. bPercent positive cells of CD3-positive
lymphocytes. 'Percent positive cells of CD3 CD8 double-positive lymphocytes.
Di osi
The mechanisms of in vivo IL-2-mediated anti-tumour re-
sponses are still not clarified. However, it is conceivable that
to attain effective cellular immunotherapy a number of prere-
quisites should be met. These include (1) effector cell activa-
tion, (2) presence or migration of effector cells in or to the
tumour site and (3) specific recognition and killing of the
tumour target cells by the effector cells. During IL-2 treat-
ment, NK effector cells as well as T lymphocytes become
activated (Janssen et al., 1993), and the latter cells have been
shown to migrate to the site of the tumour (Fisher et al.,
1989; Pankonin et al., 1990). However, in RCC patients, who
are in fact the best responding patient group, an overall
response rate of only approximately 20% to IL-2 therapy is
attained (Rosenberg et al., 1989). Resistance to IL-2 therapy
might be due to an inability of the effector cells to specifically
recognise and/or kill the tumour cells. BsMAbs that are able
to bind to both tumour cells and effector cells might add
such specificity to the IL-2 treatment. Furthermore, it is
speculated that, in addition to the IL-2-induced activation,
the BsMAb might provide a necessary co-stimulatory signal
by cross-linkling the IL-2-activated T lymphocytes to tumour
cells through their CD3 complex. In this study we investi-
gated the feasibility of a combination treatment of i.v.
BsMAb and s.c. IL-2 therapy. To prevent aspecific immune
activation or toxicity that could arise from binding of the
BsMAb through its Fc part to FcR-positive cells such as
monocytes, F(ab'), fragments of BIS-1 were used in the
present study. Acute toxicity, however, was encountered after
administration of BIS-1 F(ab'), with chills, peripheral
vasoconstriction, dyspnoea, fever and release of cytokines
such as TNF-x and IFN-y. These phenomena led to the
conclusion that the MTD of BIS1 F(ab')2 given as a 2 h
infusion is 5 ig kg-'. Recently, other investigators have
reported severe toxicity of a similar nature with high systemic
release of TNF-a and IFN--y after administration of 1 mg of
a F(ab'} BsMAb in a patient with ovarian carcinoma. In this
study no concomitant IL-2 was given (Tibben et al., 1993). In
the present study we also found elevated levels of TNF-x and
IFN-y. It remains to be resolved whether the observed tox-
icity in the higher doses of the present study is still the result
of aspecific stimulation of the monocyte/macrophage system
or whether it is induced by specific BIS-1 F(ab'}-mediated
T-cell activation, or both. The observed toxicity appears to
be unrelated to MOC31 binding alone, since the EGP-2-
recognising antibody MOC31 can be given to patients in a
dose of at least 50 mg kg' without any toxic side-effects
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(unpublished results). Anti-CD3-directed antibodies (com-
plete Ig with an intact Fc portion). however, have shown to
be toxic in cancer patients with a MTD of also approx-
imately 5 yg kg-' (400iLg total dose). However, neurotoxicity
with an onset of 12 h after infusion was dose limiting in this
setting (Buter et al., 1993). The observed toxicity therefore
appears to be related to the combined (i.e. bispecific) binding
activity of BIS-1 F(ab')2. T-cell activation, which could pos-
sibly induce toxicity, requires not only binding of BIS-I
F(ab')2 to CD3 but also clustering of the CD3 molecules
(Schwab et al.. 1985). Since the BIS-1 F(ab')2 has only a
monovalent binding site to the CD3 molecule, clustering of
CD3 molecules and therefore triggering of T-cell activation is
thought to be possible only by immobilisation of BIS-1
F(ab'). via its EGP-2 binding site. Since no EGP-2-positive
circulating (blood) cells are present, it is speculated that
BIS-1 F(ab'), might have reacted with tumour cells, or pos-
sibly some normal epithelia, after leaving the blood circula-
tion. Subsequently, either in situ or newly extravasated T
lymphocytes could have been triggered through cross-linking
of the CD3 complexes by BIS-1. A more likely explanation is
that BIS-1 F(ab')2 bound preferentially to T lymphocytes in
the circulation. After extravasation of some of these cells.
possibly induced by IL-2, these BIS-1 F(ab')2-loaded cells
may react with EGP-2 on tumour or epithelia. The tumour-T
cell interaction might subsequently trigger the production of
secondary cytokines such as TNF-a and IFN-y. resulting in
the enhanced extravasation of both lymphocytes and mono-
cytes. as we observed in the present study. In vivo binding of
BIS-1 F(ab')z to peripheral blood T lymphocytes was evalu-
ated ex vivo both functionally by a 51Cr-release assay and
immunocytologically using a sensitive indirect staining
method for flow cytometry. For the 51Cr-release assay. per-
formed to evaluate also functional binding of BIS-1. PBMCs
obtained from the patients just prior to and directly after the
infusion of BIS-1 were used. Figure 3 shows that in vivo
BIS-1 F(ab')2-loaded T lymphocytes were able to specifically
lyse EGP-2-positive tumour cells in vitro. Although the E T
ratio of 100:1 is of little clinical relevance, it is indicative for
the functional binding of BIS-l F(ab')2 in vivo. At 3 jg kg-1
BIS-1 F(ab')2 up to approximately 45% of the maximal
obtainable cytotoxicity against EGP-2-positive target cells
could be measured. Owing to the partial loss of BIS-1 F(ab')2
during isolation (see Figure 2), this finding is probably an
underestimation of the actual in vivo capacity to exert anti-
tumour activity. The SCLC cell lines GLC-1 and GLC-lM13
are relatively resistant to LAK activity (own observation),
and as a result no cytotoxicity was measured in the absence
of BIS-1 F(ab')2. which might have been expected because of
the in vivo activation of NK cells by IL-2. At 5jg kg-' the
target cell killing capacity of PBMCs after the infusion was
found to be approximately 50% of the cytotoxicity observed
with addition of an optimal concentration of BIS-1 to the
assay. However, this was mainly because of the substantially
lower maximal inducible cytotoxicity after the infusion with
BIS-1 F(ab'). as compared with the maximal cytotoxic
capacity before the infusion at this dose.
This last phenomenon appears to be related to the ob-
served rapid reduction in the number of PBMCs in the
peripheral blood during the infusion of 5 jig kg-' BIS-
F(ab')2. A reduction in PBMCs occurred to a much lesser
extent at 3 jig kg-' BIS-1 F(ab')2 (see Figures 5 and 6).
However, the low number ofcirculating PBMCs itself cannot
explain the reducing killing capacity of the isolated PBMCs
since the cytotoxicity assays were performed at a fixed E T
ratio. Lymphocyte subset analysis of blood samples taken
before and after infusion with 5 gg kg-' BIS-1 F(ab')2
showed, in addition to the general disappearance of PBMCs,
a preferential reduction in the percentage of LFA-la-bright
and HLA-DR-positive cells within the CD3 CD8 double-
positive lymphocyte population (see Table III). whereas the
percentage of CD3- and CD8-positive cells was not altered
by the infusion. The LFA-lIc-bright T-cell population has
been described as the main population responsible for
cytolytic activity (Morimoto et al.. 1987; Tsubota et al..
1989). The importance of LFA-1 for the induction of target
cell lysis is also indicated from the observation that ICAM-1-
negative target cells are relatively resistant to lysis by
BsMAb-redirected cytolytic effector cells (Stotter et al.. 1989;
Braakman et al.. 1990; Rivoltini et al.. 1991: Webb et al..
1991). Furthermore. LFA-lac-bright cells have been shown to
leave the circulation during acute immune responses (Hviid et
al.. 1991). As discussed above. extravasation of these cells
might have been initiated by the TNF-a produced during the
infusion with BIS-1. TNF-a is known to induce up-regulation
of endothelial adhesion molecules such as ICAM-1 and E-
selectin that are involved in the migration of leucocytes
(Nickoloff & Griffiths. 1989; Vogetseder et al., 1989: Graeves,
1992: Zimmerman et al., 1992). Since LFA-la-bright cells
have high avidity for both ICAM-1 and -2 (Diamond et al..
1991). this might explain the reduction of especially CD3
CD8 LFA-Ix-bright positive T lymphocytes from the circula-
tion. which subsequently explains the observed decreased
maximal tagret cell killing in vitro after infusion with
5 tLg kg-' BIS-l F(ab')2. The production of IFN-y in addition
to TNF-m. as observed after treatment with 5 tgkg-' BIS-1
F(ab').. can be taken as a further indication of BIS-l-induced
T-cell activation.
We observed one partial response in 14 evaluable patients
who were unresponsive to initial s.c. IL-2 monotherapy. This
is in line with the cytotoxic capacity of the redirected cells
observed in *itro. although a late response to IL-2 cannot be
excluded. BsMAb-redirected T lvmphocytes, in contrast to
genuine HLA-restricted cytotoxic T lymphocytes. are able to
exert their lytic capacity only once towards a relevant target
cell. Redirected killing capacity can be restored, however, by
adding new BsMAbs (Blank-Voorthuis et al.. 1993). Therefore.
to obtain better anti-tumour responses, it might be necessary
to give BIS-1 F(ab')2 more than once to the patient.
In conclusion. BIS-1 F(ab')2 can be given to cancer
patients with a MTD of 5 pg kg-' as a 2 h infusion. when
combined with IL-2. BIS-1 F(ab')> can be detected on
peripheral blood T lymphocytes both cytologically and func-
tionally upon i.v. administration of the BsMAb. At 5;Lg kg-'
BIS-1 F(ab')2 a rapid induction ofTNF-x and IFN-y produc-
tion is observed and a transient leucopenia with a preferential
depletion of LFA-la-bright CD8-positive T lymphocytes
from the blood is seen. The wide applicability of the EGP-2
antibody warrants further investigations to fully exploit the
full potential of this kind of immunotherapy.
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